-
S Tag Peptide: Practical Fusion Tag Workflow
2026-09-24
S Tag Peptide supports recombinant protein detection and can be incorporated into fusion-tag workflows where protein solubility improvement or antibody-based detection is needed. The supplied peptide is water- and DMSO-soluble but ethanol-insoluble; use a genetically encoded S-peptide fusion tag for recombinant expression, and do not assume the free peptide alone provides a complete purification or expression solution.
-
Neticonazole Hydrochloride in Cell Assay Workflows
2026-09-24
This scenario-led guide explains how to evaluate Neticonazole Hydrochloride (SKU C8715) in viability, proliferation, cytotoxicity, antifungal, and exploratory colorectal cancer research. It separates documented product properties from workflow suggestions and highlights assay controls, solubility, storage, and evidence limitations.
-
ROCK Inhibition as a Translational Control Point
2026-09-23
Y-27632 dihydrochloride offers researchers a selective way to perturb ROCK signaling, but its greatest value comes from pairing mechanistic control with careful model design. This article connects cytoskeletal biology to stem-cell and cancer research, using schizophrenia iPSC lines to illustrate both the promise and limits of translational model building.
-
BMAL1 Phase Separation in Circadian Transcription
2026-09-23
Gao et al. identify BMAL1 as a phase-separating clock factor whose N-terminal intrinsically disordered region organizes dynamic nuclear condensates. These condensates recruit CLOCK and transcriptional cofactors at E-box DNA, linking BMAL1 organization to rhythmic transcription and behavioral timing.
-
Cisplatin Assays: From DNA Damage to Resistance
2026-09-22
Cisplatin and CDDP remain powerful tools for cancer research, but assay interpretation depends on separating DNA damage from compensatory survival signaling. This guide translates a cisplatin-resistant lung cancer study into practical, resistance-aware experimental design.
-
Hyperthermia Sensitizes BRCA2-Proficient Ovarian Cancer
2026-09-22
Mei et al. show that hyperthermia can reduce BRCA2 protein and increase niraparib sensitivity in BRCA2-proficient ovarian carcinoma models. The study provides a mechanistic rationale for combining thermal treatment with PARP inhibition to extend synthetic-lethal strategies beyond tumors with pre-existing BRCA2 defects.
-
MK-4827 (Niraparib) Workflow for PARP Studies
2026-09-21
Build reproducible PARP-inhibitor assays with MK-4827 (Niraparib), from BRCA-mutant benchmarking to hyperthermia-sensitized ovarian cancer models. This workflow links DNA damage repair inhibition to practical viability, apoptosis, and RAD51-foci readouts while highlighting controls that expose resistance mechanisms.
-
H3K18 Lactylation in Post-ICH White Matter Injury
2026-09-21
This mouse study identifies microglial H3K18 lactylation as a potentially protective response after intracerebral hemorrhage, linking lactate metabolism and p300/CBP-dependent chromatin regulation to white matter repair. Its inhibitor experiments also show that reducing lactate production and blocking the lactylation writer do not produce identical outcomes, an important consideration for mechanism-focused experimental design.
-
R2 Retrotransposon Insertions and DNA Repair Pathways
2026-09-20
McIntyre, Horton, and Collins identify distinct host DNA-repair routes that stabilize either intact or truncated insertions initiated by an R2 retrotransposon protein. Their PRINT-based study connects target-primed reverse transcription to post-synthesis junction formation and second-strand repair, clarifying how non-LTR retrotransposons can generate stable genomic insertions.
-
Phagocytic Giant Cancer Macrophages in Blood
2026-09-19
A 2025 Cancer Letters study reframes circulating phagocytic polyploid giant cancer macrophages, or CAMLs, as clinically informative and biologically active cells rather than cellular debris. In a prospective, multi-institutional cohort, CAMLs correlated with disease progression and displayed self-renewing, proangiogenic, and overlapping myeloid, epithelial, and endothelial features.
-
From Podocyte Pathways to Better Viability Data
2026-09-18
A translational perspective on how AO/PI Staining Solution can strengthen viability measurements in diabetic nephropathy research, using phillygenin pathway evidence to connect molecular mechanism with reproducible fluorescence-based cell counting.
-
Mithramycin A: A Mechanism-to-Assay Guide
2026-09-18
Mithramycin A is an anticancer antibiotic for dissecting G-C-rich transcriptional control, c-myc regulation, and differentiation. This guide connects its established cancer-biology uses with a rigorous assay framework inspired by the miR-24-3p/Sp1/PI3K study, while separating evidence from exploratory applications.
-
GSK 2837808A: A Flux-Resolved LDHA Strategy
2026-09-17
GSK 2837808A provides a selective way to interrogate LDHA-dependent lactate production without treating glycolysis as a single process. This article develops a flux-resolved framework for connecting glucose consumption reduction with the NAT1–ENO1–lactate–PD-L1 axis while separating validated findings from exploratory cancer metabolism research.
-
Lactate Workflows for Metabolic–Immune Research
2026-09-17
Use L-lactate as both a quantitative metabolic readout and a controlled signaling input across glycolysis, hypoxia, mitochondrial stress, and tumor–immune models. This workflow emphasizes compartment-specific sampling, fresh dosing, and mechanistic controls that distinguish lactate production from lactate-driven PD-L1 regulation.
-
MK-4827 (Niraparib) Lab Guide
2026-09-16
A scenario-based guide to using MK-4827 (Niraparib), a potent and selective PARP-1/-2 inhibitor, in cell viability, proliferation, and cytotoxicity workflows. It explains assay design, solvent handling, resistance models, data interpretation, and vendor-selection considerations for SKU A3617.